Exelixis Inc. (NASDAQ:EXEL) fell 0.1% during trading on Friday . The company traded as low as $7.95 and last traded at $8.15, with a volume of 7,419,874 shares traded. The stock had previously closed at $8.14.

A number of research firms recently commented on EXEL. Leerink Swann restated an “outperform” rating and set a $10.00 price target (up from $8.00) on shares of Exelixis in a research report on Tuesday, June 21st. Cowen and Company restated an “outperform” rating on shares of Exelixis in a research report on Tuesday, June 7th. Finally, Stifel Nicolaus increased their price target on Exelixis from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Tuesday, April 26th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Exelixis presently has a consensus rating of “Buy” and a consensus target price of $7.63.

The company’s 50-day moving average price is $7.26 and its 200 day moving average price is $5.15. The stock’s market cap is $1.86 billion.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, May 4th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The business had revenue of $15.40 million for the quarter, compared to analysts’ expectations of $9.11 million. During the same period in the previous year, the business earned ($0.18) EPS. The firm’s revenue was up 63.8% on a year-over-year basis. Equities research analysts predict that Exelixis Inc. will post ($0.83) earnings per share for the current fiscal year.

In other Exelixis news, Director Lance Willsey purchased 40,000 shares of the company’s stock in a transaction dated Monday, May 9th. The stock was bought at an average cost of $4.97 per share, for a total transaction of $198,800.00. Following the completion of the transaction, the director now owns 548,273 shares in the company, valued at $2,724,916.81. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Several large investors have added to or reduced their stakes in EXEL. ProShare Advisors LLC increased its stake in Exelixis by 11.4% in the fourth quarter. ProShare Advisors LLC now owns 215,541 shares of the biotechnology company’s stock worth $1,216,000 after buying an additional 22,096 shares during the last quarter. California State Teachers Retirement System increased its stake in Exelixis by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 417,800 shares of the biotechnology company’s stock worth $2,356,000 after buying an additional 6,682 shares during the last quarter. Finally, Tekla Capital Management LLC acquired a new stake in Exelixis during the fourth quarter worth $5,775,000.

Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.